Cite
HARVARD Citation
Gillison, M. et al. (n.d.). 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors. Journal for immunotherapy of cancer. p. A415. [Online].